The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer

Cancers
Alexios MatikasJohn Souglakos

Abstract

Despite the high prevalence of colorectal cancer in a continuously aging population and the substantial advances in the treatment of metastatic disease during the past decade, the treatment of elderly patients with advanced, unresectable or metastatic colorectal cancer is a clearly unmet need. Since older patients are under-represented or even excluded from randomized trials, the evidence that oncologists use as guidance is weak. However, small prospective studies, pooled analyses and observational studies show that combination approaches are safe, efficacious and feasible in the geriatric population with metastatic colorectal cancer. The use of biologic agents targeting angiogenesis and the epidermal growth factor receptor, which have been shown to clearly improve outcomes in multiple prospective trials in patients with advanced colorectal cancer, is a vital component of the aforementioned combination approaches. Herein, we review all available data concerning the management of elderly patients with these agents and underscore the differences between this age subgroup and younger patients.

References

Apr 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R MattioliP Lippe
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergDaniel J Sargent
Sep 27, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maurizio Scaltriti, José Baselga
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce J GiantonioUNKNOWN Eastern Cooperative Oncology Group Study E3200
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemRafael G Amado
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard S HochsterEric Hedrick
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarOliver Rosen
Apr 3, 2009·The New England Journal of Medicine·Eric Van CutsemPhilippe Rougier
May 2, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN First BEAT investigators
Nov 12, 2009·Journal of Cancer Research and Clinical Oncology·James CassidyUlrich-Peter Rohr
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BokemeyerP Koralewski
Jun 7, 2011·The New England Journal of Medicine·Caroline RobertJedd D Wolchok
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arti HurriaWilliam P Tew
Jan 5, 2012·British Journal of Cancer·C F JehnD Lüftner
Jan 19, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey A MeyerhardtDeborah Schrag
Apr 25, 2012·Journal of Cancer Research and Clinical Oncology·S AbdelwahabA Mahmoud
Oct 10, 2012·Nature Reviews. Gastroenterology & Hepatology·Riccardo A Audisio, Demetris Papamichael
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Oct 22, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Josep TaberneroCarmen J Allegra
Dec 21, 2013·Science·Jennifer Couzin-Frankel
May 3, 2014·Therapeutic Advances in Medical Oncology·Z KordatouDemetris Papamichael
Jul 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PapamichaelM Aapro
Sep 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN ESMO Guidelines Working Group
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02060188
NCT01876511
NCT01309126
NCT01622543

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Anti-cancer Agents in Medicinal Chemistry
M J Molina-GarridoA Mora-Rufete
World Journal of Clinical Oncology
Peter GeorgesGregory J Kubicek
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Muhammad A KhattakTimothy J Price
© 2021 Meta ULC. All rights reserved